Podcast: Bridging Chasms in Bladder Cancer Care: An Expert Case-based Review of Treatment Selection and Sequencing in an Era of Therapeutic Novelty
This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing and the role of antibody-drug conjugates (ADCs) in subsequent lines of therapy for advanced disease. To conclude the session, activity attendees will get to apply the therapeutic principles they’ve learned to real-world clinical scenarios which will focus on patient-centric treatment selection and sequencing, as well as recognition, mitigation, and management of treatment-related adverse events.
Physicians specializing in genitourinary oncology and urologic oncology as well as members of the interprofessional health care team active in treating patients with bladder cancer
- Examine recent evolutions in the bladder cancer management calculus across the totality of the disease
- Appraise the expanding clinical trial evidentiary base for ADCs in metastatic disease, including regulatory updates, recent readouts, and current expert consensus guideline recommendations.
- Discuss the unique clinical potential of ADCs in mUC, particularly in subsequent lines of therapy, and evaluate ongoing and prospective ADC clinical trials, both as monotherapy and as part of combinatorial regimens with ICIs.
- Using real-world cases that incorporate the patient voice, design evidence-supported bladder cancer treatment plans, both in first-line and post-progression, by integrating guideline recommendations with patient-specific and disease-specific factors (i.e., performance status, renal function, PD-L1 expression, FGFR mutation, cytopathology, urinary markers, etc.).
- Recognize, mitigate, and manage treatment-related adverse events in patients with advanced bladder cancer.
Not an official event of the 2023 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.
Presented by Creative Educational Concepts, LLC (CEC Oncology) in collaboration with the Bladder Cancer Advocacy Network (BCAN).
Supported through an independent educational grant from Gilead.
5 min Welcome and Introductions/Pre-test
20 min A Paradigm in Flux: Diving Deep into Evolving Standards of Care Across the Bladder Cancer Disease Continuum
20 min ADCs in mUC: The Expanding Evidentiary Base, Evolving Consensus Guidelines, and Patient-Centric Considerations
30 min Case-driven Catalysts: An Expert Roundtable Discussion on Evidence-based Treatment Sequencing in Bladder Cancer
15 min Conversations with the Experts/Audience Q&A/Post-test
Petros Grivas, MD, PhD (Activity Chair)
Professor, Division of Medical Oncology
University of Washington School of Medicine
Clinical Director, Genitourinary Cancers Program
Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Sam S. Chang MD, MBA
Patricia and Rodes Hart Endowed Chair of Urologic Surgery
Professor of Urology and Oncology
Chief Surgical Officer, Vanderbilt Ingram Cancer Center
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine and Urology
Weill Cornell Medicine
Weill Cornell Medical Center
New York, NY
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Petros Grivas, MD, PhD–has disclosed that he is an advisor or consultant to 4D Pharma PLC, Aadi Bioscience, AstraZeneca, Astellas Pharma, Boston Gene, Bristol Myers Squibb, CG Oncology Inc., Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, G1 Therapeutics, Genentech, Gilead Sciences, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, MSD, Mirati Therapeutics, Pfizer, PureTech, Roche, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, and UroGen. His institution has received grants from Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, MSD, Mirati Therapeutics, Pfizer, and QED Therapeutics.
Sam S. Chang MD, MBA–has disclosed that he is an advisor or consultant to BMS, GLG, Janssen, KDx Diagnostics, mIR, Pfizer, Prokarium, Tu Therapeutics, Urogen, and Virtuoso Surgical.
Scott T. Tagawa, MD, MS, FACP–has disclosed that he receives research support from Abbvie, Amgen, Astellas, AstraZeneca, Atlab, Aveo, Bayer, BMS, Boehringer Ingelheim, Clovis, Dendreon, Endocyte, Genentech, Gilead, Immunomedics, Inovio, Janssen, Karyopharm, Lilly, Medivation, Millennium, Merck, Newlink, Novartis, POINT Biopharma, Progenics, Rexahn, Sanofi, and Seattle Genetics. He is an advisor or consultant to AAA/Novartis, Abbvie, AIkido Pharma, Amgen, Bayer, Blue Earth, Clarity, Clovis, Convergent Therapeutics, Dendreon, Eisai, EMD Serono, Endocyte, Genentech, Genomic Health, Immunomedics, Janssen, Karyopharm, Medivation/Astellas, Merck, Myovant, Pfizer, POINT Biopharma, QED, Sanofi, Seattle Genetics, Telix Pharma, and Tolmar. He also receives other financial or material support from Immunomedics, Gilead, and Weill Cornell.
Bashir Al Hussein Al Awamlh, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Bishoy Morris Faltas, MD–has disclosed that he receives research support from Eli Lilly. He is an advisor or consultant to Astra Biosciences, Ltd., Astrin Biosciences, Inc., BostonGene, Gilead, Guardant, Immunomedics, Janssen, Merck, Natera, and QED therapeutics. He receives patent royalties from Immunomedics/Gilead. He also receives other financial or material support from Axiom Healthcare Strategies, LLC and Urotoday.
Katherine Lee, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a CE request form, statements of credit will be issued within 30 days
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation